Exelixis
Trade Exelixis 24 hours a day, five days a week on Robinhood.
Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.About EXEL
Exelixis, Inc. operates as an oncology company, which focuses on discovering, developing, and commercialization of new medicines for difficult-to-treat cancers. Its products include cabometyx, cometriq, and cotellic.
EXEL Key Statistics
Stock Snapshot
The current Exelixis(EXEL) stock price is $44.50, with a market capitalization of 11.41B. The stock trades at a price-to-earnings (P/E) ratio of 15.82.
On 2026-02-14, Exelixis(EXEL) stock moved within a range of $42.85 to $44.50. With shares now at $44.50, the stock is trading +3.9% above its intraday low and 0.0% below the session's peak.
Trading activity shows a volume of 2.06M, compared to an average daily volume of 2.89M.
Over the past 52 weeks, Exelixis(EXEL) stock has traded between a high of $49.62 and a low of $32.38.
Over the past 52 weeks, Exelixis(EXEL) stock has traded between a high of $49.62 and a low of $32.38.
EXEL News
Exelixis, the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Robert Burns from H.C. Wainwright reiterated a Buy rating on the...
H.C. Wainwright raised the firm’s price target on Exelixis (EXEL) to $54 from $52 and keeps a Buy rating on the shares. The firm updated the company’s model pos...
Exelixis ((EXEL)) has held its Q4 earnings call. Read on for the main highlights of the call. Valentine's Day Sale - 70% Off Unlock hedge fund-level data and po...
Analyst ratings
50%
of 22 ratingsMore EXEL News
Exelixis (EXEL) is back in focus after reporting fourth quarter earnings that topped market expectations, along with full-year results and fresh progress on its...
Image source: The Motley Fool. Tuesday, February 10, 2026 at 5:00 p.m. ET Call participants President and Chief Executive Officer — Michael Morrissey Chief Fin...
Reports Q4 revenue $598.663M, consensus $598.68M. “Exelixis (EXEL) delivered strong results in 2025 and is well positioned for a breakout year in 2026,” said Mi...
In early February 2026, Exelixis, Inc. reported that the FDA accepted its New Drug Application for zanzalintinib plus atezolizumab to treat previously treated a...
People also own
Similar Marketcap
This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.
Popular Stocks
This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset
Newly Listed
This list is generated by showing companies that recently went public.